A Phase 1/2, First-in-Human, Safety and Efficacy Study of NUV-1511 in Adult Patients With Advanced Solid Tumors
Latest Information Update: 25 Sep 2024
Price :
$35 *
At a glance
- Drugs NUV 1511 (Primary)
- Indications Advanced breast cancer; HER2 negative breast cancer; Ovarian cancer; Pancreatic cancer; Pancreatic ductal carcinoma; Prostate cancer; Solid tumours
- Focus Adverse reactions; Therapeutic Use
- Sponsors Nuvation Bio
- 14 Mar 2024 According to Nuvation Bio media release, first patient has been dosed in this trial.
- 14 Mar 2024 Status changed from planning to recruiting, according to Nuvation Bio media release.
- 15 Jan 2024 New trial record